NewsEvents

Your Yourlocation: Home > Clinical observation of tiotropium bromide(136310-93-5) combined with N - acetylcysteine in the treatment of chronic obstructive pulmonary disease

Third People's Hospital of Nantong City, Joe into the study of tiotropium combined with N-acetylcysteine in the treatment of chronic obstructive pulmonary disease clinical observation, the study found that compared with tiotropium alone, tiotropium bromide(136310-93-5) NAC treatment of COPD more significant clinical efficacy, improve lung function in patients with more significant, lower recurrence rate, and safety quite. The article published on 2015 04 "China pharmacy".The aim of this study was to investigate the clinical efficacy and safety of tiotropium bromide(136310-93-5) plus N-acetylcysteine (NAC) in the treatment of chronic obstructive pulmonary disease (COPD).

METHODS: Ninety patients with COPD were randomized equally into the control and observation groups. Patients in the control group were treated with tiotropium bromide(136310-93-5) inhalation alone (18 μg / time qd). The patients in the control group Treatment with NAC effervescent tablets (600 mg / time, qd). The course of treatment in both groups was 4 weeks. The clinical efficacy, blood gas index, pulmonary function index, adverse reaction and recurrence of the two groups were observed before and after treatment.

The results showed that the total effective rate of the observation group was significantly higher than the control group, the difference was statistically significant (P <0.05). After treatment, the arterial oxygen partial pressure [p (O2)], oxygen saturation (SpO2) and p (O2) in the observation group were significantly higher than those before treatment in this group, the two groups of arterial blood carbon dioxide (P (CO2)) were significantly lower than those in the control group and the levels of p (O2) and SpO2 in the observation group were significantly higher than those in the control group and p (CO2) in the observation group were significantly lower than those in the control group (FEV1), forced vital capacity (FVC) and forced expiratory volume (FEV1 / FVC) at 1 s and FEV1 / FEV1 / FVC in the control group were significantly higher than those in the control group (P <0.05) The FEV1, FVC and FEV1 / FVC of the observation group were significantly higher than the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05), but the recurrence rate in the control group was significantly higher than that in the observation group (P <0.05).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved